Iambic Therapeutics Announces Poster Presentation for IAM1363, a Clinical Stage Type II HER2 Inhibitor, at the 2024 ASCO Annual Meeting
May 23 2024 - 5:00PM
Business Wire
Iambic Therapeutics, a clinical-stage biotechnology company
developing novel therapeutics using its unique AI-driven discovery
platform, today announced a poster presentation highlighting the
ongoing Phase 1 study of IAM1363, a selective and brain-penetrant
inhibitor of HER2 signaling for the treatment of HER2-driven
cancers. The TIP (trials in progress) poster will be shared at the
American Society for Clinical Oncology (ASCO) Annual Meeting,
taking place May 31-June 4 in Chicago.
IAM1363 is a small molecule inhibitor of wild-type and oncogenic
mutant HER2 proteins, designed to expand the therapeutic index
compared to available HER2 inhibitors and to avoid toxicities from
off-target inhibition of EGFR. In preclinical studies, IAM1363 has
demonstrated over 1000-fold selectivity for HER2 compared to EGFR,
a promising pharmacokinetic and safety profile, preferential tumor
enrichment, and penetrance of the central nervous system. In HER2
tumor models, including intracranial tumor models, IAM1363 has
demonstrated favorable efficacy and tolerability compared to
benchmark tyrosine kinase inhibitors and HER2-targeted
antibody-drug conjugates. IAM1363 was identified using Iambic’s
AI-driven discovery platform and is now being evaluated in a Phase
1 clinical study, IAM1363-01 (NCT06253871).
Poster Presentation Details:
Title: IAM1363-01: A phase 1/1b Study of a Selective and
Brain-Penetrant HER2 inhibitor for HER2-driven Solid Tumors
Abstract Number: TPS3186
Session Title: Developmental Therapeutics—Molecularly
Targeted Agents and Tumor Biology
Location: Hall A, Poster board 318a
Date and Time: June 1, 9:00am-12:00pm CT
Presenter: Alex A. Adjei, MD, PhD, FACP, Chief of the
Cleveland Clinic’s Cancer Institute
About Iambic Therapeutics
Founded in 2019 and headquartered in San Diego, California,
Iambic Therapeutics is disrupting the therapeutics landscape with
its unique AI-driven drug-discovery platform. Iambic has assembled
a world-class team that unites pioneering AI experts and
experienced drug hunters with strong track records of success in
delivering clinically validated therapeutics. The Iambic platform
has been demonstrated to deliver high-quality, differentiated
therapeutics to clinical stage with unprecedented speed and across
multiple target classes and mechanisms of action. The Iambic team
is advancing an internal pipeline of clinical assets to address
urgent unmet patient needs. Learn more about the Iambic team,
platform, and pipeline at iambic.ai.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523853529/en/
Jason Glashow Glashow Strategic Communications for Iambic
Jason.Glashow@iambic.ai